Хламидийная инфекция и аспириновая бронхиальная астма

A frequency of C.pneumoniae and C.trachomatis infection was studied in 44 aspirin-induced asthma (AsBA) patients and 65 asthma patients with no aspirin intolerance (NBA) compared with certain immune system parameters and clinical course of the disease. The controls were 21 healthy persons. Each second bronchial asthma patient was found to have chronic Chlamydia infection that was confirmed by secretory IgA level >1:8. AsBA patients prevalently have IgA titre >1:32, an increased sera immune complexes level and a decreased monocyte migration inhibition index. A reduction in melatonin synthesis and associated immune disorders in AsBA patients probably facilitate the infection to transform to chronic state as soon as 91.7% of the patients younger 50 years show a high IgA-antibodies level associated with early occurrence of bronchial asthma. These data display a necessity of timely detection of Chlamydia infection and differentiated approach to antibiotics administration for asthma exacerbations in such the patients.Изучена частота инфицирования С.pneumoniae и С .trachomatis в сопоставлении с некоторыми показателями системы иммунитета и клиническим течением заболевания у 44 больных аспириновой бронхиальной астмой (АсБА) и 65 больных бронхиальной астмой без непереносимости аспирина (НБА). Контрольную группу составил 21 здоровый человек. Установлено, что у каждого второго больного бронхиальной астмой имеется хроническая хламидийная инфекция, о чем свидетельствует наличие секреторных IgA в титрах >1:8. У больных АсБА доминирует титр антител 1дА>1:32, что сочетается с увеличением в крови циркулирующих иммунных комплексов и снижением индекса торможения миграции моноцитов. Возможно, у больных АсБА снижение продукции мелатонина и связанные с этим изменения системы иммунитета способствуют ранней хронизации инфекции, о чем свидетельствует выявление высокого титра IgA-антител у 91,7% больных в возрасте до 50 лет, что сочетается с ранним появлением у них инфекционно-зависимого варианта течения астмы. Полученные данные указывают на необходимость своевременной диагностики хламидийной инфекции и дифференцированного подхода к выбору антибактериальной терапии при обострениях заболевания у этого контингента больных

Virus-associated chronic endometritis: treatment options

Aim. To evaluate the effectiveness of Alloferon (Allokin-alfa) in the complex treatment of virus-associated chronic endometritis (CE) in patients with infertility, papillomavirus infection (PVI) persisting in the uterine cavity, and recurrent herpes-virus infection localized in the genital area. Materials and methods. A prospective (n=33) open randomized (2:1) study was conducted to assess the efficacy of Alloferon (Allokin-alfa) in the complex treatment of CE in patients with infertility, PVI, and recurrent herpes-virus infection, aged 25 to 37 years (median age 31 [29; 32.5] years). All patients received valacyclovir therapy at 500 mg once daily for 30 days from the day of randomization. Patients in the main group (n=21) simultaneously with the start of antiviral therapy received Allokin-alfa as 9 subcutaneous injections once every two days (one injection every other day). The uterine cavity microbiota of the patients was assessed 3 months after treatment, and histological and immunohistochemical studies of endometrial biopsy specimens were performed. Results. The microbiological data analysis showed HPV elimination in 71.4% vs 16.7% of patients in the alloferon and control groups, respectively (2 7.102, p=0.008). Also, in the main group, a significant decrease in the severity of CE (2 27.586, p0.001) and p16ink4a protein expression levels (2 6.17, p=0.013) were observed. Conclusion. In the treatment of virus-associated CE, the addition of alloferon to virus-suppressive therapy leads to higher rates of HPV elimination from the uterine cavity and significantly reduces the severity of CE

Prerequisites for the creation of an atlas of postcovid inflammation as a way of personalized pharmacotherapy, as well as predicting and preventing organ and systemic dysfunctions

SARS-CoV-2 is a novel coronavirus that has been identified as the cause of the 2019 coronavirus infection (COVID-19), which originated at Wuhan city of PRC in late 2019 and widespread worldwide. As the number of patients recovering from COVID-19 continue to grow, it’s very important to understand what health issues they may keep experiencing. COVID-19 is now recognized as an infectious disease that can cause multiple organ diseases of various localization. It is against this background that a new term was introduced: post-acute post-COVID-19 syndrome characterized by several persistent symptoms inherent in the acute phase of the disease, as well as the occurrence of delayed and (or) long-term complications beyond 4 weeks from the onset of the disease. The work reflected in this article revealed a portrait of a patient with post-COVID-19 syndrome, the most common complications of this period, as well as the mechanisms of their development and the resulting metabolic, cellular, tissue disorders leading to the tissue and organ dysfunctions. A comprehensive biochemical and immunological screening was carried out using the example of three clinical cases to identify the most significant disorders in these patients and to correlate with their clinical status over time. In point of fact, such patients were diagnosed with vascular dysfunction factors (development of endothelial dysfunction), metabolic dysfunction factors (metabolic acidosis, mitochondrial dysfunction, carbohydrate metabolism disorder, insulin resistance, altered branched-chain and aromatic amino acid metabolism), neurological disorder factors (neurotoxicity of the resulting metabolites), immunological disorder factors (decreased efficiency of detoxification systems, secondary immunodeficiency, risk of secondary bacterial infection)

Reasonable antimicrobial therapy in patients with pyodermatosis

The data are given about the history of the invention and development of antimicrobial therapy in the XX-th and the beginning of the XXI-th centuries. There are presented data on the pharmacological effects of antibacterial agents from different groups that are used for the treatment of patients with pyodermatosis, dose schedules, pharmacokinetics, adverse effects, contraindications, and medicine interactions. The main causes leading to the formation of resistant microorganism strains are pointed. Advances of broad-spectrum antibacterial antibiotics for treatment the pyodermic patients are demonstrated on the example of amoxicillin+clavulinic acid, josamycin and doxycycline monohydrate. The arguments justifying the need to refuse empiric administration of antibacterial therapy are presented. To select a rational causal initial therapy of patients with pyoderma it is necessary to use the results of microbiological study of etiology and pathogenic microflora sensitivity to antimicrobial preparations

Chlamydia trachomatis serovar distributions in Russian men and women: a comparison with Dutch serovar distributions

The data on serovar distributions of Chlamydia trachomatis - the most diagnosed sexually transmitted infection (STI) worldwide - are important for epidemiologic purposes and transmission studies but are completely lacking in Russia. The aim of the current study is to determine the serogroup and serovar distributions in Russian men and women and compare these data with Dutch serogroup and serovar distributions. In Russian men and women, serogroup B was the most prevalent (46%), followed by the intermediate serogroup (I group; 33%) and serogroup C (21%). The distribution was comparable between men and women. The serogroup distribution was similar to the previously published distribution in Dutch cohorts. However, on a serovar level statistically very significant differences were observed, reaching up to P < 0.0001. The serovars B and G/Ga had higher prevalences compared with the reported Dutch prevalences, while serovars F, H, I/Ia, J and K had lower prevalences compared with the Dutch studies. In conclusion, this is the first report of Russian C. trachomatis serovar/serogroup distributions. Serogroup B is the most prevalent, followed by serogroup I and serogroup C with no statistical differences on the serogroup level. However, significant differences between Russia and the Netherlands were observed in the distribution of C. trachomatis serovar